CLINICAL TRIALS PROFILE FOR RITUXIMAB

Biosimilar Clinical Trials for rituximab

This table shows clinical trials for biosimilars. See the next table for all clinical trials

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01459887 ↗	Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's Lymphoma	Completed	Shanghai CP Guojian Pharmaceutical Co., Ltd.	Phase 3	2006-09-01	CD20, the protein which is expressed on the surface of all mature B cells, is active in many B-cell lymphomas that express this molecule such as Diffuse Large B Cell Lymphoma (DLBCL), the most frequently occurring subtype of non-Hodgkin lymphomas. In clinical practice, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone combination chemotherapy (CHOP) is still considered one of the standard treatment to DLBCL. CMAB304(Retuxira), the chimeric monoclonal antibody is designed to targeted against CD20 for treatment of lymphoma diseases. This trial aimed to observe the safety and efficacy of CMAB304, by added CMAB304 to CHOP chemotherapy regimen compared with CHOP chemotherapy alone.
NCT01459887 ↗	Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's Lymphoma	Completed	Shanghai CP Guojian Pharmaceutical Co.,Ltd.	Phase 3	2006-09-01	CD20, the protein which is expressed on the surface of all mature B cells, is active in many B-cell lymphomas that express this molecule such as Diffuse Large B Cell Lymphoma (DLBCL), the most frequently occurring subtype of non-Hodgkin lymphomas. In clinical practice, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone combination chemotherapy (CHOP) is still considered one of the standard treatment to DLBCL. CMAB304(Retuxira), the chimeric monoclonal antibody is designed to targeted against CD20 for treatment of lymphoma diseases. This trial aimed to observe the safety and efficacy of CMAB304, by added CMAB304 to CHOP chemotherapy regimen compared with CHOP chemotherapy alone.
NCT01759030 ↗	Study of Safety and Efficacy of BCD-020 Comparing to MabThera in Patients With Rheumatoid Arthritis	Completed	Biocad	Phase 3	2012-12-01	The purpose of this study is to prove that efficacy, safety and immunogenicity of BCD-020 is equivalent to MabThera when used in combination with methotrexate for the treatment of patient with rheumatoid arthritis

All Clinical Trials for rituximab

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00001337 ↗	Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma	Active, not recruiting	National Cancer Institute (NCI)	Phase 2	1993-05-08	5-Drug Combination Chemotherapy with Hematologic Toxicity Attenuation. EPOCH: Etoposide, VP-16, NSC-141540; Prednisone, PRED, NSC-10023; Vincristine, VCR, NSC-67574; Cyclophosphamide, CTX, NSC-26271; Doxorubicin, DOX, NSC-123127; with Granulocyte Colony-Stimulating Factor (Amgen), G-CSF, NSC-614629....
NCT00001379 ↗	Treatment and Natural History Study of Lymphomatoid Granulomatosis	Recruiting	National Cancer Institute (NCI)	Phase 2	1995-08-07	This study will evaluate the response and long-term effects of alpha-interferon in patients with lymphomatoid granulomatosis (LYG). The disease causes proliferation of destructive cells involving the lungs, skin, kidneys, and central nervous system. Patients ages 12 and older who have LYG and who are not pregnant or breast feeding may be eligible for this study. Alpha interferon or chemotherapy, or both, will be used. Alpha interferon is a protein the body naturally produces. If patients have grade 3 disease, they will usually receive EPOCH-rituximab (EPOCH-R) chemotherapy (each letter representing a drug). If patients have grade 1 or 2 disease, the will usually receive alpha interferon. If patients have LYG after receiving alpha interferon and/or EPOCH-R, they may receive rituximab alone or with alpha interferon. Rituximab is an antibody, binding to a specific molecule (CD20) present on most B-cell lymphomas. Doses of several drugs in EPOCH-R may be increased if patients tolerated them in the previous cycle. If patients respond to EPOCH-R but still have low grade LYG, they may receive alpha interferon. Researchers will also try to obtain a biopsy of patients lesions, to help in understanding the disease. Patients self-administer alpha interferon by injection under the skin three times weekly. They will visit the clinic every 2 to 12 weeks for follow-up. Patients will receive alpha interferon for 1 year after LYG goes away, depending on response. EPOCH-R has these drugs: rituximab by vein on Day 1; prednisone by mouth on Days 1 to 5; etoposide, doxorubicin, and vincristine as a continuous intravenous infusion on Days 1 to 5; and cyclophosphamide by intravenous injection over 1 hour on Day 5. Each cycle lasts 3 weeks: 5 days of chemotherapy and 16 days of no chemotherapy. Etoposide, doxorubicin, and vincristine are infused through a small pump worn by patients. The drugs are given over 5 days through a central intravenous catheter. There are two cycles of EPOCH-R beyond a maximum response, with six cycles minimum. To reduce harm to bone marrow, patients receive granulocyte colony stimulating factor (G-CSF), self-administered by injection under the skin daily for approximately 10 days between chemotherapy cycles. If at the end of therapy, patients have a complete response, treatment will stop. If there is residual low grade disease, patients may receive alpha interferon. Alpha interferon can have flu-like side effects of headache, fever, chills, and body aches. EPOCH-R drugs can cause gastrointestinal problems, hair loss, and weakness. G-CSF can cause bone pain, body aches, and hair thinning. Chemotherapy can cause some patients to develop leukemia. This study may or may not have a direct benefit for participants. It is not certain whether the new therapy will help decrease tumors. However, knowledge gained may improve the understanding of and treatment for LYG.
NCT00001563 ↗	EPOCH Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma	Completed	National Cancer Institute (NCI)	Phase 2	1997-01-08	The prognosis of AIDS-related Non-Hodgkin's lymphoma is poor, especially in the relapsed setting. There is no standard treatment, and the few small studies that have been conducted have reported dismal outcomes. The purpose of this study is to pilot the use of EPOCH plus rituximab in previously treated AIDS-related lymphoma. Clinical endpoints of the study include toxicity and response. Progression-free and overall survival will be measured. Tumors will be evaluated for p53 mutations, p-16, bcl-2 expression, tumor proliferation, c-myc and EBV when possible....

Clinical Trial Conditions for rituximab

Condition Name

Condition Name for rituximab
Intervention	Trials
Lymphoma	286
Diffuse Large B-Cell Lymphoma	140
Chronic Lymphocytic Leukemia	134

Condition MeSH

Condition MeSH for rituximab
Intervention	Trials
Lymphoma	1283
Lymphoma, B-Cell	543
Lymphoma, Non-Hodgkin	477

Clinical Trial Locations for rituximab

Trials by Country

Trials by Country for rituximab
Location	Trials
Italy	772
China	716
Hungary	92
Denmark	87
Russian Federation	84

Trials by US State

Trials by US State for rituximab
Location	Trials
Texas	389
California	387
New York	370
Ohio	254
Illinois	243

Clinical Trial Progress for rituximab

Clinical Trial Phase

Clinical Trial Phase for rituximab
Clinical Trial Phase	Trials
PHASE4	10
PHASE3	41
PHASE2	133

Clinical Trial Status

Clinical Trial Status for rituximab
Clinical Trial Phase	Trials
Completed	909
Recruiting	570
Terminated	226

Clinical Trial Sponsors for rituximab

Sponsor Name

Sponsor Name for rituximab
Sponsor	Trials
National Cancer Institute (NCI)	326
Hoffmann-La Roche	158
M.D. Anderson Cancer Center	143

Sponsor Type

Sponsor Type for rituximab
Sponsor	Trials
Other	2845
Industry	1395
NIH	391

Rituximab: Clinical Trial Update, Market Analysis, and Projection (Global)

Last updated: April 25, 2026

What is rituximab’s clinical status and what do current trials indicate?

Rituximab is an anti-CD20 monoclonal antibody (mAb) used across hematologic malignancies and autoimmune indications. Its clinical pipeline in 2024-2026 is dominated by:

• Next-generation anti-CD20 programs (new antibodies, Fc-engineered variants, bispecifics, antibody-drug conjugates) competing for share in the same CD20-treated landscapes.
• Optimization studies that expand rituximab regimens across line of therapy, consolidation strategies, and combination backbones (especially with BTK inhibitors, immunomodulators, and chemoimmunotherapy).

Key clinical-readout themes that continue to shape practice

Across major rituximab disease areas, ongoing development clusters around four goals:

1. Earlier-line use or treatment de-escalation to reduce chemotherapy exposure while maintaining efficacy.
2. Combination regimens that improve response depth (e.g., with agents that alter B-cell receptor signaling or cellular immunity).
3. Subpopulation refinement (frailty, high-risk biology, minimal residual disease strata).
4. Switching and sequencing strategies that improve outcomes in relapsed/refractory settings.

Practical implications for a “clinical trial update” view

• In practice, rituximab’s competitive position is maintained by the breadth of established protocols (RA, NHL subtypes) and by guideline entrenchment of anti-CD20 therapy.
• The most material incremental value for manufacturers usually comes from new label expansions and protocol adoption, not from large head-to-head “breakthrough” studies, given the maturity of CD20 targets and the presence of multiple biosimilar and next-gen entrants.

Which rituximab indications drive volume, and where is competition most intense?

Rituximab is used in two broad commercial blocks:

• Oncology
  • Non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), among others.
  • Chronic lymphocytic leukemia (CLL) is also a major use-case depending on region and regimen.
• Autoimmune
  • Rheumatoid arthritis (RA) and other immune-mediated conditions are material historically, with dosing and adoption patterns varying by geography and payor design.

Competitive intensity by block

• Oncology: Highest intensity due to curative intent and regimen churn (chemoimmunotherapy vs targeted oral agents vs cellular therapy). Anti-CD20 remains a core backbone, but share migrates to agents with dosing convenience, safety differentiators, and label expansion momentum.
• Autoimmune: Competition is driven by biosimilar penetration, payer step edits, and the availability of alternative immunomodulators (JAK inhibitors, other biologics, and combination strategies).

What is the market structure for rituximab and where do biosimilars change the economics?

Rituximab markets are shaped by biosimilar availability. In many jurisdictions, biosimilars compress net pricing and increase physician adoption when tendering and payer policies favor lower acquisition cost.

Where price erosion typically shows up

• Hospital procurement markets where tendering favors lowest-cost biosimilar options.
• Multi-source formularies that allow switching, with limited clinical barriers.
• Regions where biosimilar adoption is high and prescribing is protocolized through clinical pathways.

Impact on unit economics (high-level)

• Net price declines usually outpace volume growth.
• Residual value concentrates in:
  • contract-controlled segments,
  • settings where originator branding still offers administrative or supply continuity benefits, and
  • patient subsets where clinicians prefer a specific product within the class.

How big is the rituximab market today, and what are forward-looking drivers?

Market demand drivers

Forward demand for rituximab is anchored by:

• Incidence and treatment penetration in NHL and CLL (anti-CD20 remains a first-line backbone in many regimens).
• Biosimilar affordability, which improves access in payor-restricted settings.
• Treatment sequencing after targeted therapies, where anti-CD20-based salvage strategies persist.

Forward drivers that can slow erosion

• Protocol standardization around rituximab-containing regimens.
• Switching friction that keeps some portfolios sticky (institutional preferences, pharmacy workflows, and immunogenicity monitoring protocols).

Forward headwinds

• Next-gen anti-CD20 competition and combinations that improve response rates.
• Faster adoption of new targeted agents in both frontline and relapsed settings.
• Continued price compression from biosimilar proliferation and tender cycles.

How should investors or R&D planners think about rituximab projections?

A “projection” for rituximab should be read as a volume vs net price split:

• Volume: usually stable to modestly growing in anti-CD20-heavy indications due to baseline disease burden and ongoing guideline inclusion.
• Net price: continues to decline in markets where biosimilars dominate, with occasional stabilization driven by tender cycles and supply consolidation.

Scenario framing (directional, not probabilistic)

• Base case: gradual net-price erosion with stable utilization; total market value grows slowly relative to volume.
• Downside: accelerated switching to the lowest-cost product and increased share loss to next-gen therapies in high-growth oncology segments.
• Upside: label expansions or new regimen leadership that preserve higher share among preferred anti-CD20 backbones in specific countries.

Market forecast structure for planning (what to model)

For operating planning and valuation, model the following components by geography and setting:

1) Indication mix

• NHL subtype mix shifts matter because regimen intensity and duration change with biology and line of therapy.

2) Treatment setting

• Inpatient/outpatient chemotherapy workflows, infusion capacity, and tender design change product selection.

3) Biosimilar share curve

• Market share typically follows a rapid early adoption phase, then settles into periodic tender-driven reallocation.

4) Share of regimen backbones

• Rituximab’s share depends on how often it remains in:
  • induction,
  • consolidation,
  • maintenance,
  • and salvage strategies.

What do major guideline and approval references imply about durability?

Clinical and regulatory history supports durability because rituximab is entrenched in long-standing treatment ecosystems. Anti-CD20 therapy remains central in NHL management and is represented in widely used clinical references and regulatory labels. The clinical durability is reinforced by repeated guideline inclusion and protocol adoption over time, even as targeted agents expand.

Key references include:

• FDA product labeling for rituximab (standard dosing and indication scope). Source: FDA. [1]
• EMA assessment history and product information (EU label structure). Source: EMA. [2]

Competitive landscape: where rituximab is most likely to lose share

Rituximab faces share erosion in pockets where new therapies deliver better outcomes or operational advantages:

• Relapsed and refractory pathways where targeted oral combinations can reduce chemoimmunotherapy use.
• Evolving DLBCL and FL strategies where intensified regimens and novel biologics alter selection patterns.
• Next-generation CD20 and bispecifics that can displace infusion-based mAb backbones in certain lines.

Key takeaways on clinical and market outlook

• Rituximab demand remains supported by NHL and autoimmune penetration, with anti-CD20 therapy still a durable backbone.
• Net sales are primarily pressured by biosimilar-driven net price decline and tender dynamics, even if unit volume is stable.
• New clinical readouts in 2024-2026 mainly affect regimen design and adoption patterns rather than creating a step-change in rituximab’s role.
• Market projections should be built on a volume-stability thesis paired with ongoing net-price erosion, tempered by occasional regional contract stabilization.

---

Key Takeaways

1. Rituximab’s clinical position is durable in NHL and autoimmune indications, with ongoing trials focused on regimen optimization and combinations.
2. Biosimilars dominate the competitive structure, driving sustained net price compression across many geographies.
3. Forward value growth depends more on market access and share retention (tender cycles, regimen entrenchment) than on breakthrough clinical expansion.
4. The most material risk to long-term share comes from next-gen anti-CD20 modalities and targeted-therapy regimen shifts in oncology.

---

FAQs

1) What is rituximab’s primary mechanism of action?

Rituximab is an anti-CD20 monoclonal antibody that targets B cells expressing CD20, enabling immune-mediated cytotoxicity. [1, 2]

2) What drives rituximab demand most strongly?

NHL treatment penetration and ongoing guideline-based use of anti-CD20-containing regimens are the dominant demand drivers. [1, 2]

3) How do biosimilars affect rituximab’s market outlook?

They typically accelerate net price erosion and increase product switching, making revenue growth harder to sustain even when volume remains stable.

4) Are there any signs rituximab is being displaced in oncology?

Share can shift as targeted regimens and next-gen biologics gain adoption, especially in specific relapsed and refractory settings.

5) How should projections be modeled for rituximab?

Model separate pathways for volume (utilization) and net price (tender and biosimilar share), by indication and geography, rather than relying on a single-line growth rate.

---

References

[1] U.S. Food and Drug Administration (FDA). Rituxan (rituximab) prescribing information. FDA.
[2] European Medicines Agency (EMA). Rituximab product information and assessment documents. EMA.